Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer.

@article{Kemeny2009PhaseIT,
  title={Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer.},
  author={Nancy E. Kemeny and Marinela Capanu and Michael Ian D'Angelica and William R. Jarnagin and Dana L Haviland and R Dematteo and Yaou Fong},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2009},
  volume={20 7},
  pages={1236-41}
}
BACKGROUND The purpose of the study was to determine the maximum tolerated dose of systemic oxaliplatin (oxal), 5-fluorouracil (5-FU) and leucovorin (LV) that could be administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) and dexamethasone (Dex) in the adjuvant setting after hepatic resection. METHODS Thirty-five patients with resected liver metastases were entered into a phase I trial using HAI FUDR/Dex with escalating doses of oxal and 5-FU. RESULTS The initial dose of… CONTINUE READING
35 Citations
21 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Similar Papers

Loading similar papers…